Literature DB >> 27350312

Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study.

Xiaojuan Mi1, Bradley G Hammill2,3, Lesley H Curtis2,3, Edward Chia-Cheng Lai4, Soko Setoguchi5,6.   

Abstract

Observational comparative effectiveness and safety studies are often subject to immortal person-time, a period of follow-up during which outcomes cannot occur because of the treatment definition. Common approaches, like excluding immortal time from the analysis or naïvely including immortal time in the analysis, are known to result in biased estimates of treatment effect. Other approaches, such as the Mantel-Byar and landmark methods, have been proposed to handle immortal time. Little is known about the performance of the landmark method in different scenarios. We conducted extensive Monte Carlo simulations to assess the performance of the landmark method compared with other methods in settings that reflect realistic scenarios. We considered four landmark times for the landmark method. We found that the Mantel-Byar method provided unbiased estimates in all scenarios, whereas the exclusion and naïve methods resulted in substantial bias when the hazard of the event was constant or decreased over time. The landmark method performed well in correcting immortal person-time bias in all scenarios when the treatment effect was small, and provided unbiased estimates when there was no treatment effect. The bias associated with the landmark method tended to be small when the treatment rate was higher in the early follow-up period than it was later. These findings were confirmed in a case study of chronic obstructive pulmonary disease.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Monte Carlo simulations; immortal time bias; landmark methods; observational study; survival analysis; time-varying treatment

Mesh:

Year:  2016        PMID: 27350312     DOI: 10.1002/sim.7019

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  33 in total

1.  Cardiac rehabilitation and readmissions after heart transplantation.

Authors:  Justin M Bachmann; Ashish S Shah; Meredith S Duncan; Robert A Greevy; Amy J Graves; Shenghua Ni; Henry H Ooi; Thomas J Wang; Randal J Thomas; Mary A Whooley; Matthew S Freiberg
Journal:  J Heart Lung Transplant       Date:  2017-05-23       Impact factor: 10.247

2.  Association of Cardiac Rehabilitation With Decreased Hospitalization and Mortality Risk After Cardiac Valve Surgery.

Authors:  Devin K Patel; Meredith S Duncan; Ashish S Shah; Brian R Lindman; Robert A Greevy; Patrick D Savage; Mary A Whooley; Michael E Matheny; Matthew S Freiberg; Justin M Bachmann
Journal:  JAMA Cardiol       Date:  2019-12-01       Impact factor: 14.676

3.  Outcomes of Mechanical Mitral Valve Replacement in Children.

Authors:  Chizitam Ibezim; Amber Leila Sarvestani; Jessica H Knight; Omar Qayum; Noor Alshami; Elizabeth Turk; James St Louis; Courtney McCracken; James H Moller; Lazaros Kochilas; Geetha Raghuveer
Journal:  Ann Thorac Surg       Date:  2018-09-26       Impact factor: 4.330

4.  Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

Authors:  Noelle V Frey; Pamela A Shaw; Elizabeth O Hexner; Edward Pequignot; Saar Gill; Selina M Luger; James K Mangan; Alison W Loren; Alexander E Perl; Shannon L Maude; Stephan A Grupp; Nirav N Shah; Joan Gilmore; Simon F Lacey; Jos J Melenhorst; Bruce L Levine; Carl H June; David L Porter
Journal:  J Clin Oncol       Date:  2019-12-09       Impact factor: 44.544

5.  Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.

Authors:  Linhui Hu; Alice Charwudzi; Qian Li; Weiwei Zhu; Qianshan Tao; Shudao Xiong; Zhimin Zhai
Journal:  Ann Hematol       Date:  2021-02-15       Impact factor: 3.673

6.  Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.

Authors:  Janick Weberpals; Lina Jansen; Myrthe P P van Herk-Sukel; Josephina G Kuiper; Mieke J Aarts; Pauline A J Vissers; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2017-09-01       Impact factor: 8.082

7.  Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.

Authors:  Do Kyung Kim; Hye Sun Lee; Ju-Young Park; Jong Won Kim; Ji Soo Ha; Jae Heon Kim; Won Jae Yang; Kang Su Cho
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-30       Impact factor: 4.553

8.  Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study.

Authors:  Masoud Babaei; Yesilda Balavarca; Lina Jansen; Valery Lemmens; Felice N van Erning; Liesbet van Eycken; Evelien Vaes; Annika Sjövall; Bengt Glimelius; Cornelia M Ulrich; Petra Schrotz-King; Hermann Brenner
Journal:  Int J Cancer       Date:  2017-12-04       Impact factor: 7.396

9.  Association of Cardiac Rehabilitation With Decreased Hospitalizations and Mortality After Ventricular Assist Device Implantation.

Authors:  Justin M Bachmann; Meredith S Duncan; Ashish S Shah; Robert A Greevy; JoAnn Lindenfeld; Steven J Keteyian; Randal J Thomas; Mary A Whooley; Thomas J Wang; Matthew S Freiberg
Journal:  JACC Heart Fail       Date:  2018-02       Impact factor: 12.035

10.  Warfarin Use and Mortality, Stroke, and Bleeding Outcomes in a Cohort of Elderly Patients with non-Valvular Atrial Fibrillation.

Authors:  Bradshaw Pamela J; Hung Joseph; Knuiman Matthew; Briffa Thomas G; Nedkoff Lee; Katzenellebogen Judith M; Rankin Jamie M; Sanfilippo Frank M
Journal:  J Atr Fibrillation       Date:  2019-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.